Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
about
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.Clinical applications of PD-L1 bioassays for cancer immunotherapy.Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast CancerPD-L1 Expression in Lung Cancer.Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerEstablishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.Description of the immune microenvironment of chondrosarcoma and contribution to progression.Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations.Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients.Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.PD-L1 expression testing in non-small cell lung cancer.Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
P2860
Q30276649-DB332212-C502-4E83-A0A9-A8870CFF2EDEQ30489890-070F44F9-5734-4E98-BC02-0447B39E295AQ33702815-298EA4E7-0F4A-4E59-AD50-1116145515C6Q36261405-F051B7AB-F345-4AC7-B4CA-B605616D94C0Q37316596-A81D1A22-96E5-438F-8C37-5CAB1F776345Q37704352-865819CD-4B21-47C5-8BCC-49933BF05E7DQ37706604-7B33A1B1-4CFE-4971-B603-50C42070D9ECQ38375652-1B4AC065-312B-4820-9EBA-A9AD47B0824BQ38718943-2975ECBD-64CE-4670-BA90-3F9565943FD1Q38742013-B3749027-9167-4919-95F3-3CCF262F16B9Q38836875-FFD6C473-91B0-4BF2-8632-F2050E220E94Q38839108-1273617A-D829-4096-962F-172348DA48CEQ38847321-4B4F56D0-520F-4396-A4DD-FA276E0E02B8Q38998427-8006D0AA-CCC5-4EF9-A492-6A3DC28EFD31Q39118471-F7BF8491-A393-4F75-884F-A87BE07CB22BQ39194722-94C40396-A69F-4A91-9904-9A2530E9CD3BQ39426272-76B7674E-1314-4741-B1C9-C8F07459E9FDQ41201725-E0AADE6D-1903-4A2F-A064-8A101B6F8E45Q41708934-4C447DE8-60A9-4367-93B9-D430DE2265CDQ41770303-86EA42DF-C017-4ECD-ABCC-CE644FDAB1E3Q42391326-04CC1851-9C8A-445C-8F3C-E6518E8C7685Q46037895-D768F75C-B7E6-427E-9189-5F3058102105Q46228932-2B886450-D661-4E19-9A53-B6823988A82BQ46308773-7043A28C-9CF2-404F-BBA7-398F1E0F33D9Q46450730-324796B8-2D27-4FD6-A9FC-D1B976F868C6Q46532764-7A1710A6-7BCD-48F2-B44B-76C0484EDBF7Q46682797-D563ED5F-B19A-4453-B26B-E9A0FDE52F44Q46990125-F73EF3B7-363E-466C-BE16-C6D4EEC9AED5Q47105905-8AC1CD25-130E-466C-9EB1-213C4C3313C4Q47117334-A9ADCF87-F1BC-41E7-A62A-B9589BADB8C9Q47164059-9C613B71-8501-496F-BDFF-C142A0828EB0Q49181142-DD928231-3E09-4FE6-B397-1F6AA102EE6FQ49494082-603DD5F1-BDC8-4433-956E-0600BC58C65BQ49920182-F4903EAE-7F54-479D-922E-28BD253EB9ECQ51213139-44FAFC46-68EC-42F0-98E3-850644EF2C74Q52584388-12A38DC7-2AA1-4F57-B3FC-00A506969A89Q58795231-C136B08B-0A91-4399-8591-BE5E2AEA04C5
P2860
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development of an automated PD ...... for non-small cell lung cancer
@ast
Development of an automated PD ...... for non-small cell lung cancer
@en
type
label
Development of an automated PD ...... for non-small cell lung cancer
@ast
Development of an automated PD ...... for non-small cell lung cancer
@en
prefLabel
Development of an automated PD ...... for non-small cell lung cancer
@ast
Development of an automated PD ...... for non-small cell lung cancer
@en
P2093
P2860
P1476
Development of an automated PD ...... for non-small cell lung cancer
@en
P2093
Clive Taylor
Hector D Inzunza
James Novotny
John Cogswell
Pauline Simmons
Therese Phillips
Xiaoling Zhang
P2860
P304
P356
10.1097/PAI.0000000000000256
P577
2015-08-25T00:00:00Z